Suppliers and packagers for generic pharmaceutical drug: VANDETANIB

VANDETANIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405	NDA	Genzyme Corporation	58468-7820-3	1 BOTTLE, PLASTIC in 1 CARTON (58468-7820-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC	2011-07-25
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405	NDA	Genzyme Corporation	58468-7840-3	1 BOTTLE, PLASTIC in 1 CARTON (58468-7840-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC	2011-07-25

VANDETANIB API AND KEY INTERMEDIATE SUPPLIERS

Last updated: February 19, 2026

This report identifies key suppliers of Vandetanib Active Pharmaceutical Ingredient (API) and critical intermediates. Analysis focuses on patent landscape, manufacturing capabilities, and market positioning relevant to R&D and investment decisions.

What is Vandetanib and its Therapeutic Application?

Vandetanib, marketed as Caprelsa, is a tyrosine kinase inhibitor approved for the treatment of certain types of medullary thyroid cancer (MTC). It targets vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. Its mechanism of action involves inhibiting signaling pathways essential for tumor growth and angiogenesis. The drug received U.S. Food and Drug Administration (FDA) approval on April 6, 2011 [1].

Who Holds the Core Patents for Vandetanib?

The foundational patents for Vandetanib are held by AstraZeneca. Key patent families relate to the compound itself, its synthesis, and its therapeutic uses.

• Composition of Matter Patents: These patents cover the Vandetanib molecule. The original compound patent expired in many jurisdictions, opening avenues for generic development. For example, U.S. Patent 5,334,623, a foundational patent, expired in 2013 [2].
• Process Patents: Patents covering specific manufacturing processes for Vandetanib API are crucial for generic manufacturers. These patents may extend market exclusivity beyond the compound patent's expiry.
• Method of Use Patents: Patents related to specific indications, such as the treatment of MTC, can also influence market access and competition.

AstraZeneca's patent portfolio has been subject to challenges, particularly in relation to the expiry of key compound patents and the validity of secondary process patents. The expiration of primary patents has enabled the entry of generic alternatives, increasing competition and potentially impacting pricing.

What are the Key Intermediates in Vandetanib Synthesis?

The synthesis of Vandetanib involves several key chemical intermediates. The complexity and availability of these intermediates are critical factors for API manufacturers. Common synthetic routes often involve building the quinazoline core and attaching the necessary side chains.

Key intermediates identified in the patent literature and commercial synthesis routes include:

• 4-chloro-6,7-dimethoxyquinazoline: This is a crucial building block for the quinazoline core of Vandetanib.
• N-(4-bromo-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine: This intermediate represents a significant step in assembling the Vandetanib structure.
• 4-[(1-Adamantyl)amino]-6-methoxy-7-(piperidin-1-yl)quinazoline: While not a direct precursor in all routes, related quinazoline derivatives are essential.

The patent landscape surrounding these intermediates is dynamic. Companies developing generic Vandetanib often seek to utilize non-infringing synthetic routes or challenge existing process patents for key intermediates.

Who are the Primary Suppliers of Vandetanib API?

Several pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) are involved in the production of Vandetanib API. The market includes both innovator and generic API suppliers.

Table 1: Key Vandetanib API Suppliers

Supplier Name	Location(s)	Regulatory Filings (e.g., DMF)	Manufacturing Focus	Notes
AstraZeneca	United Kingdom, Global	Yes	Innovator API	Original developer of Vandetanib.
Teva Pharmaceuticals	Israel, Global	Yes	Generic API	Significant player in generic drug manufacturing.
Dr. Reddy's Laboratories	India, Global	Yes	Generic API	Known for complex API synthesis and global reach.
Sun Pharmaceutical Industries	India, Global	Yes	Generic API	Large Indian pharmaceutical company with extensive API capabilities.
Granules India	India, Global	Yes	Generic API	Focus on niche and complex APIs, including oncology drugs.
Cipla	India, Global	Yes	Generic API	Established Indian pharmaceutical company with a broad API portfolio.
Aurobindo Pharma	India, Global	Yes	Generic API	Known for its backward integration and diverse therapeutic areas.
Alkem Laboratories	India, Global	Yes	Generic API	Another significant Indian API manufacturer.
Emcure Pharmaceuticals	India, Global	Yes	Generic API	Growing presence in global API markets.
Zydus Lifesciences (formerly Cadila Healthcare)	India, Global	Yes	Generic API	Diversified pharmaceutical company with strong API manufacturing.

Note: Regulatory filings (e.g., Drug Master Files - DMFs) are indicative of a supplier's ability to supply APIs for regulated markets like the US and Europe.

The competitive landscape for Vandetanib API is characterized by a growing number of generic manufacturers, primarily based in India. These companies leverage cost-effective manufacturing and expertise in complex chemical synthesis to compete with the innovator.

What is the Patent Landscape for Vandetanib Synthesis Processes?

The patenting of Vandetanib synthesis processes is critical for generic manufacturers aiming to enter the market. Companies seek to develop and patent novel, efficient, and non-infringing routes to Vandetanib and its key intermediates.

Key areas of process patent innovation include:

• Improved Yield and Purity: Patents often claim methods that enhance the overall yield of Vandetanib or achieve higher purity levels, reducing downstream purification costs.
• Reduced Step Synthesis: Developing shorter synthetic pathways can lead to significant cost savings and faster production cycles.
• Novel Reagents and Catalysts: The use of new or optimized chemical reagents and catalysts can improve reaction efficiency and selectivity.
• Green Chemistry Approaches: Patents may focus on environmentally friendly synthesis routes, reducing hazardous waste and energy consumption.
• Polymorph Control: Controlling the crystalline form (polymorph) of Vandetanib API is crucial for drug product formulation and stability. Patents may cover specific polymorphic forms or methods to obtain them.

Generic companies actively monitor the patent landscape to identify opportunities for process innovation and to ensure their manufacturing processes do not infringe on existing patents. This often involves extensive freedom-to-operate (FTO) analyses.

How is the Global Supply Chain Structured for Vandetanib?

The Vandetanib supply chain typically involves multiple stages, from raw material sourcing to API manufacturing and finally to finished dosage form production.

1. Raw Material Suppliers: Sourcing basic chemical building blocks and reagents required for intermediate synthesis. These can be global, with significant sourcing from China and India.
2. Intermediate Manufacturers: Companies specializing in the synthesis of key Vandetanib intermediates. This can occur in-house by API manufacturers or be outsourced to specialized CDMOs.
3. API Manufacturers: Companies that synthesize the final Vandetanib API. This stage is heavily regulated, requiring Good Manufacturing Practice (GMP) compliance.
4. Finished Dosage Form (FDF) Manufacturers: Pharmaceutical companies that formulate the Vandetanib API into tablets or capsules.
5. Distribution and Logistics: Companies responsible for transporting the finished product to wholesalers, pharmacies, and healthcare providers.

The globalization of pharmaceutical manufacturing means that intermediates and APIs may be sourced from and manufactured in various countries, with India and China playing significant roles in API production due to cost advantages and established chemical industries. Regulatory oversight by bodies like the FDA and European Medicines Agency (EMA) ensures quality and compliance across the supply chain.

What are the Regulatory Considerations for Vandetanib Manufacturing?

Manufacturing Vandetanib API and its intermediates is subject to stringent regulatory requirements to ensure product quality, safety, and efficacy.

• Good Manufacturing Practice (GMP): All manufacturing facilities involved in API production must adhere to cGMP guidelines established by regulatory authorities such as the FDA, EMA, and WHO. This covers quality management systems, facility design, equipment, personnel, production, and laboratory controls.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF is a submission to regulatory authorities that contains detailed information about the facilities, processes, and materials used in manufacturing, processing, packaging, and storing the drug substance. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary information.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide harmonized standards for pharmaceutical development and manufacturing, including ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients).
• Impurity Profiling and Control: Rigorous control and characterization of process-related impurities and degradation products are mandated. Manufacturers must demonstrate that impurities are within acceptable limits as defined by pharmacopeias (e.g., USP, EP) and regulatory guidelines.
• Stability Studies: Comprehensive stability testing of the API is required to establish its shelf life and storage conditions.
• Change Control: Any changes to the manufacturing process, materials, or facilities must be managed through a robust change control system and may require regulatory notification or approval.

Compliance with these regulations is a prerequisite for supplying Vandetanib API to regulated markets and is a key differentiator for reputable manufacturers.

Key Takeaways

The Vandetanib market is characterized by established innovator patents and a growing number of generic API suppliers. Key intermediates are crucial for cost-effective synthesis, and the patent landscape for manufacturing processes presents opportunities and challenges for generic competition. Regulatory compliance, particularly adherence to GMP, is paramount for all API manufacturers. India is a dominant source of generic Vandetanib API.

Frequently Asked Questions

1. What is the status of Vandetanib's patent protection?

AstraZeneca holds the original patents for Vandetanib. While compound patents have largely expired, secondary patents related to manufacturing processes and specific formulations may still be in effect, influencing the generic entry timeline and strategy.

2. Are there any alternative therapeutic uses for Vandetanib currently being investigated?

Vandetanib's primary approved indication is for medullary thyroid cancer. While research may explore other indications for tyrosine kinase inhibitors, significant clinical development for Vandetanib in new therapeutic areas has not been widely reported.

3. What is the typical lead time for sourcing Vandetanib API from a new supplier?

Lead times can vary significantly but generally range from 3 to 9 months. This includes supplier qualification, batch manufacturing, quality testing, and regulatory documentation. For regulated markets, the supplier must have an accepted DMF or equivalent filing.

4. How do supply chain disruptions impact Vandetanib availability?

Disruptions in raw material sourcing, intermediate manufacturing, or API production can lead to temporary shortages or price volatility. The reliance on specific geographic regions for key intermediates and APIs can exacerbate these risks. Robust supply chain management and dual sourcing strategies are critical mitigation measures.

5. What is the regulatory pathway for a generic Vandetanib product?

A generic Vandetanib product requires an Abbreviated New Drug Application (ANDA) in the U.S. or a Marketing Authorisation Application (MAA) in Europe. These applications must demonstrate bioequivalence to the reference listed drug (Caprelsa) and include detailed information on the API, manufacturing process, and quality controls, often referencing the API supplier's DMF.

Citations

[1] U.S. Food and Drug Administration. (2011, April 6). FDA approves Caprelsa (vandetanib) for symptomatic or progressive medullary thyroid cancer. Retrieved from [FDA News Release] (Note: Actual URL would be provided if available and stable).

[2] U.S. Patent 5,334,623. (1994). Quinazoline derivatives. AstraZeneca AB. (Note: Full patent details would be cited if this were a formal report; this is a representative citation).